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ABSTRACT
Introduction: Barrett’s oesophagus (BO), a
metaplastic condition affecting the lower oesophagus
due to long-standing gastro-oesophageal reflux and
chronic inflammation, is a precursor lesion for
oesophageal adenocarcinoma (OADC). There is no
clinical test to predict which patients with BO will
progress to OADC. The British Society of
Gastroenterology recommends endoscopic surveillance
of patients with BO. Epigenetic changes have been well
characterised in the neoplastic progression of ulcerative
colitis to colonic carcinoma, another gastrointestinal
cancer associated with chronic inflammation. This
systematic review protocol aims to identify and
evaluate studies which examine epigenetic biomarkers
in BO and their association with progression to OADC.
Methods and analysis: All prospective and
retrospective primary studies, and existing systematic
reviews investigating epigenetic markers including DNA
methylation, histone modification, chromatin
remodelling, micro and non-coding RNAs of all types
will be eligible for inclusion. Eligible patients are those
over the age of 18 with BO, BO with dysplasia, OADC
or unspecified oesophageal cancer. A comprehensive
search of bibliographic databases using combinations
of text and index words relating to the population,
prognostic markers and outcome will be undertaken
with no language restrictions. Results will be screened
by 2 independent reviewers and data extracted using a
standardised proforma. The quality and risk of bias of
individual studies will be assessed using the Quality in
Prognostic Studies (QUIPS) tool. A narrative synthesis
of all evidence will be performed with key findings
tabulated. Meta-analysis will be considered where
studies and reported outcomes are considered
sufficiently homogeneous, both clinically and
methodologically. Findings will be interpreted in the
context of the quality of included studies. The
systematic review will be reported according to
PRISMA guidelines.
Ethics and dissemination: This is a systematic
review of completed studies and no ethical approval is
required. Findings from the full systematic review will
be submitted for publication and presentation at
national and international conferences which will
inform future research on risk stratification in patients
with BO.
Review registration number: CRD42016038654.
INTRODUCTION
The incidence of oesophageal adenocarcin-
oma (OADC) has dramatically increased in
recent years to 5.7 per 100 000 for women
and 14.1 per 100 000 for men in the UK.1 2
Unfortunately the majority of patients
present with advanced unresectable disease
with an overall 5-year survival of <13%.3 The
ﬁve-year survival rates improve considerably
to 39% with localised disease.4 Barrett’s
oesophagus (BO), is deﬁned as an oesopha-
gus in which any portion of the normal distal
squamous epithelial lining is replaced by
metaplastic columnar epithelium which is
Strengths and limitations of this study
▪ Systematic review protocol following PRISMA-P
guidelines, including description of key meth-
odological steps.
▪ Rationale for a new systematic review in this area
based on scoping searches.
▪ Exhaustive search strategy likely to capture all
relevant published literature on epigenetic
markers for progression of Barrett’s oesophagus
and oesophageal adenocarcinoma.
▪ Heterogeneity of published research anticipated
(differing epigenetic biomarkers studied, vari-
ation of study design, sampling methods and
follow-up length).
▪ Above may limit certain epigenetic markers to
narrative evidence synthesis
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clearly visible endoscopically (≥1 cm) above the gasto-
oesophageal junction (GOJ) and conﬁrmed histopatho-
logically from oesophageal biopsies.5 BO arises due to
long-standing gastro-oesophageal reﬂux disease (GORD)
and chronic inﬂammation and is a precursor lesion for
OADC with progression through the metaplasia-dysplasia-
carcinoma sequence.6 The likelihood of developing
OADC is increased 1.7 times in patients with GORD,
increasing to 10.6 times with BO.7 The incidence of
OADC has risen in parallel with increasing obesity and
GORD in Western populations.1 With rising rates of
obesity the incidence of OADC is predicted to further
increase.8 Currently there is no robust way of predicting
which patients with BO will progress to OADC. The
current clinical biomarker for the progression of BO is
the presence of worsening cellular dysplasia, also known
as intraepithelial neoplasia, on histological examination
of serial oesophageal biopsies.5 The presence of high-
grade dysplasia (HGD), and recently low-grade dysplasia
(LGD), triggers intervention.9 As a result, the British
Society of Gastroenterology recommends endoscopic
surveillance of patients with BO and the American
College of Gastroenterology endorses screening of high-
risk patients for BO.5 10 Endoscopic surveillance is inva-
sive, expensive and despite rigorous biopsy protocols,
dysplasia and early cancers can be missed. Importantly a
meta-analysis published in 2012 demonstrated lower risk
for progression of non-dysplastic BO than previously
reported with a pooled 0.33% (95% CI 0.28% to 0.38%)
annual incidence of OADC.11 The annual incidence
rate of OADC for patients with BO with HGD is 7–
19%.12–14
Epigenetics is an emerging ﬁeld which describes
mechanisms of alteration of gene regulation and ex-
pression without changing the genetic code.15 These
regulatory mechanisms are important in normal
human development, for example, silencing of the
X-chromosome in females.16 Epigenetic changes may be
inherited but can also be acquired through environmen-
tal factors such as cigarette smoking.17 Epigenetic change
can occur through various methods. The most recog-
nised are covalent modiﬁcations including DNA methyla-
tion, histone modiﬁcation and altered gene expression
by non-coding RNAs.15 DNA methylation occurs when
DNA methyltransferase adds a methyl group (CH3) to a
DNA base. In humans this is most commonly a cytosine
base creating 5-methylcytosine.15 Methylation, which
occurs at gene promoter (CpG) sites causes downregula-
tion of these genes. It is thought that the mechanism
responsible is the projection of a methyl group into the
DNA groove which physically blocks transcription.18
Histone modiﬁcation is a post-translational alteration to
histone proteins which package DNA into nucleosomes
and eventually chromosomes by winding DNA around
them. If the histone structure is altered, the DNA cannot
be correctly unravelled and cannot be correctly tran-
scribed. The above modiﬁcations are carried over when a
cell divides and can be inherited.19 Many different types
of non-coding RNAs have been discovered to alter gene
expression by targeting coding messenger RNA (mRNA)
after its transcription from DNA. Both micro RNAs
(miRNA) and long non-coding RNAs have been impli-
cated in gene regulation. These bind to mRNA molecules
and cause them to be denatured and halt protein transla-
tion and cause genetic silencing.20
Abnormal silencing of a tumour suppressor or a DNA
repair gene through hypermethylation of their CpG pro-
moter sites may cause the cells to grow uncontrollably
and lead to tumourigenesis. Epigenetic changes have
been well characterised in the neoplastic progression of
ulcerative colitis,21–24 another tumour arising as a result
of chronic inﬂammation progressing through dysplasia
and resulting in colonic carcinoma.25 Intriguingly epi-
genetic change has been shown to occur early in this
process before neoplasia has developed.26 The
Enhanced Neoplasia Detection and Cancer Prevention
in Chronic Colitis (ENDCaP-C) trial is investigating
whether a panel of methylated biomarkers detected in
endoscopic biopsy samples can be used as a tool in con-
junction with screening colonoscopy to help risk stratify
patients who are at higher risk of progressing to carcin-
oma.27 With the latest next generation sequencing and
methylation microchip arrays, it is possible to detect epi-
genetic changes accurately and reproducibly even in
archival tissue samples. In light of this there is a need to
consolidate the literature on epigenetic changes in
Barrett’s carcinogenesis to determine if such changes
provide a method of risk stratifying patients who are at
risk of progression to OADC.
A scoping search was performed using MEDLINE, the
Cochrane Library and internet sources to identify any sys-
tematic reviews or meta-analyses on epigenetic biomar-
kers in BO and oesophageal cancer (OC). It revealed in
excess of 2000 primary studies which are relevant for
inclusion into the proposed systematic review. No system-
atic reviews which draw together all aspects of epigenetic
change within the ﬁeld of Barrett’s carcinogenesis were
identiﬁed. Nine systematic reviews and meta-analyses
were identiﬁed28–36 which included mixed patient popu-
lations with OADC and oesophageal squamous cell car-
cinoma (OSCC) with only three reviews incorporating
patients with BO.31 32 36 These studies concentrated on a
single type of epigenetic alteration with four investigating
DNA methylation28–30 and three looking at miRNA
expression.31–34 The remaining two studies investigated
genetic alterations in progression of BO to OADC.35 36
Based on these results, we believe that a systematic review
on this topic is both timely and required.
Research aims
This systematic review will identify and summarise
studies which examine epigenetic biomarkers in BO and
their association with progression to OADC with the aim
of consolidating the literature and informing future
laboratory work.
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METHODS AND ANALYSIS
This systematic review protocol has been reported in
accordance with PRISMA-P guidelines.
Selection criteria
Population: All patients over the age of 18 with BO, BO
with dysplasia, OADC or unspeciﬁed OC will be
included.
Prognostic markers: Epigenetic markers including DNA
methylation, histone modiﬁcation, chromatin remodel-
ling, miRNAs and non-coding RNAs of all types will be
included.
Outcome: Progression from non-dysplastic BO with or
without intestinal metaplasia to BO with LGD, HGD or
OADC.
Study design: All prospective and retrospective primary
studies, and systematic reviews will be included.
Publication type: Abstract and full texts will be included
with exclusion of letters and editorials
Exclusion criteria: OSCC and established OCs with no evi-
dence of a pre-existing BO diagnosis will be excluded.
Case reports, narrative reviews, in vitro studies (eg, cell
lines), studies of genetic mutations, studies using bio-
markers to predict a response to treatment (eg, chemo-
therapy) will be excluded. A decision was made to
exclude animal studies, as scoping searches indicated
that there were comparatively few (compared with
human studies), and therefore were likely to add hetero-
geneity to an already heterogeneous evidence base. In
addition, we concluded that issues relating to transfer-
ability of experimental ﬁndings from animal models to a
clinical setting would occur.
Search strategy
The following electronic bibliographic databases will be
searched from inception: EMBASE, MEDLINE,
MEDLINE in Process, DARE, CDSR, Cochrane Central.
Conference (Conference Proceeding Citation Index,
Zetoc) and registers of clinical trials (ClinicalTrials.gov
and ICTRP) will also be searched. Reference lists of
identiﬁed studies and systematic reviews will be screened
for any relevant primary studies that were not retrieved
from the database searches. Date or language restric-
tions will not be placed on searches. A search strategy
will be developed using combinations of text and index
words relating to the population, exposure and
outcome, such as: ‘Barrett’s Oesophagus’, ‘epigenetic’,
‘DNA methylation’, ‘marker’ and ‘oesophageal adeno-
carcinoma’. A sample search strategy for MEDLINE is
shown in online supplementary appendix 1.
Study selection
This will be a two-step process. Titles and abstracts iden-
tiﬁed in our literature search will be screened independ-
ently by two reviewers using prespeciﬁed screening
criteria. These are broadly based on whether the studies
ﬁrst include measuring epigenetic markers in patients
with OADC and second whether these patients have
progressed from BO to OADC. Full texts of any poten-
tially relevant articles will be obtained and subjected to
the full inclusion criteria. Any discrepancies found will
be referred to a third reviewer. The study selection
process will be documented using the PRISMA ﬂow
diagram. Endnote X7 will be used as reference manage-
ment software and decisions on inclusion or exclusion
will be recorded.
Data extraction
Data will be extracted by two independent reviewers
using an agreed, standard data extraction form. Any dis-
agreements which cannot be resolved by discussion will
be referred to a third reviewer who will act as an
arbitrator.
Data will be extracted on the following study
characteristics:
1. Study design characteristics—for example, prospect-
ive or retrospective and length of follow-up.
2. Population—for example, tissue samples from
patients with BO or patients with OADC looking
retrospectively at BO samples, patient demographics.
3. Prognostic markers—epigenetic markers including
DNA methylation, histone modiﬁcation, chromatin
remodelling, miRNAs and non-coding RNAs of all
types.
4. Outcomes—progression from non-dysplastic BO with
or without intestinal metaplasia to BO with LGD,
HGD or OADC.
Assessment of study quality
The quality and risk of bias of individual studies will be
assessed using the Quality in Prognostic Studies
(QUIPS) tool.37 This tool will review each individual
study in six criteria: study participation, study attrition,
prognostic factor measurement, outcome measurement,
study confounding factors, and statistical analysis and
reporting. We anticipate that due to the difﬁculty in
obtaining samples and the length of follow-up required
to assess progression from BO to OADC, there may be
signiﬁcant sample selection bias. Eligible studies are
likely to be subject to confounding, with main confound-
ing factors relating to age, obesity, smoking and alcohol
intake. The risk of bias assessment will therefore include
an assessment of which confounding factors (if any)
have been measured and whether they were adjusted for
in the design or analysis of the study. There may be dif-
ferences in how robust the methods are for measuring
the prognostic markers and the outcome; for example,
published guidelines recommend conﬁrmation of HGD
by two independent pathologists.5 These factors need to
be assessed carefully for each study so that a judgement
can be made on whether epigenetic changes seen in
these studies are truly reﬂective of Barrett’s carcinogen-
esis on a population level and whether they can be
reproduced easily and accurately for screening purposes.
We do not anticipate ﬁnding any studies that test models
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predicting progression based on patient factors and
panels of epigenetic markers.
Evidence synthesis
A narrative synthesis of all evidence will be performed
with key ﬁndings tabulated. An assessment of clinical
and methodological heterogeneity will be undertaken in
order to determine the feasibility of meta-analysis. The
main sources of heterogeneity are likely to be subtype of
biomarker, study design, length of follow-up, sampling
interval and experimental technique and equipment
used to demonstrate epigenetic change. Meta-analysis
may be performed if there are multiple studies reporting
on individual biomarker types such as DNA methylation,
histone methylation, histone acetylation, miRNA and
non-coding RNA providing the same outcomes (and
outcome statistic) are reported. Results will most likely
be presented as different risks of progression, for
example, relative risk (RR) of progression with and
without the prognostic marker. Where studies have
reported time to progression, HRs will be extracted
where possible.
Studies of different study design and those reporting
adjusted or unadjusted results will be analysed separately.
RR of progression from non-dysplastic BO to BO with
LGD, HGD or OADC will be calculated where possible.
Adjusted results, for example, from multivariate analyses,
are likely to be more informative in terms of the prog-
nostic ability of a given marker in the context of other
potential prognostic factors (such as clinical and lifestyle
factors). Where meta-analyses are performed, a
random-effects model will be more appropriate to
account for between-study heterogeneity. Heterogeneity
will also be measured statistically using the I2 statistics
and the χ2 test. Publication bias will be assessed (by gen-
erating Funnel plots) only if more than 10 studies are
present in each meta-analysis. The strength of the
overall body of evidence generated by the systematic
review will be assessed using the GRADE approach
(Grades of Recommendation, Assessment, Development
and Evaluation Working Group).38 The full systematic
review will be reported according to PRISMA
guidelines.39
DISCUSSION
This systematic review will aim to comprehensively iden-
tify studies reporting on epigenetic changes in progres-
sive BO. The results will help to inform future research
on risk stratiﬁcation and a personalised approach to
endoscopic surveillance in patients with BO. The ﬁnd-
ings may inform future research into the optimisation of
the Barrett’s surveillance programmes using epigenetic
markers as part of a multimodal screening tool.
ETHICS AND DISSEMINATION
This is a systematic review of completed studies and no
ethical approval is required. Findings from the full
systematic review will be submitted for publication and
presentation at national and international conferences
which will inform future research on risk stratiﬁcation in
patients with BO.
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